MAI Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

MAI Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301	Hold	526	–	–	﹤0.01%	4531
2025 Q4	$349	Hold	526	–	–	﹤0.01%	3930
2025 Q3	$1.87K	Hold	526	–	–	﹤0.01%	3323
2025 Q2	$1.05K	Sell	526 -50	-9%	-$114	﹤0.01%	3609
2025 Q1	$1.44K	Sell	576 -33	-5%	-$93	﹤0.01%	3038
2024 Q4	$1.8K	Buy	+609	New	+$1.71K	﹤0.01%	3050
2023 Q2	–	Sell	-19,498	Closed	-$72.9K	–	1127
2023 Q1	$72.9K	Sell	19,498 -1,093	-5%	-$5.73K	﹤0.01%	997
2022 Q4	$63.6K	Sell	20,591 -41,197	-67%	-$155K	﹤0.01%	965
2022 Q3	$282K	Sell	61,788 -26,925	-30%	-$267K	0.01%	716
2022 Q2	$2.34M	Buy	+88,713	New	+$3.13M	0.04%	232

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAI Capital Management's VTGN Position: Q1 2026 in Review

MAI Capital Management held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 526 shares worth $301. The position accounts for ﹤0.01% of the portfolio, ranked #4531.

MAI Capital Management first reported a position in VTGN in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.34M in Q2 2022. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

MAI Capital Management held 526 shares of VistaGen Therapeutics worth $301 as of Q1 2026.
MAI Capital Management left its VistaGen Therapeutics share count unchanged in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4531 holding.
MAI Capital Management first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 10 quarters since.
MAI Capital Management's VistaGen Therapeutics position peaked at $2.34M in Q2 2022.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.